Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

1,639 resultsPage 33 of 137, newest first
  1. Biotech & pharmaM34 Inc.R. Jude Samulski Receives Inaugural Founders Award from Chinese Society of Gene & Cell TherapyHistoric first-ever honor makes the M34 co-founder the only scientist to receive Founders Awards from leading gene and cell therapy societies across three continents — M34 Inc. today announced that its co-founder and chief scientific officer,...
  2. FinanceTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
  3. FinanceTeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette SyndromeTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data include a post hoc analysis of safety and efficacy during the initial 8 weeks of treatment with ecopipam, long-term efficacy and safety from an interim analysis of an ongoing open-label extension (OLE) study, post hoc subgroup analyses and preclinical receptor selectivity findings.
  4. FinanceJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric PatientsTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome.1,2 The review evaluates current treatment limitations and details how selectively targeting D1 receptors in the brain’s direct motor pathway may offer a differentiated, non-antipsychotic approach for managing tics in pediatric patients.1
  5. HealthcareAdaptogenics Health Corp.Adaptogenics Appoints Accomplished Peptide Scientist Dr. J. David Warren as Chief Executive OfficerAdaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics" or the "Company") is pleased to announce the appointment of J. David Warren, Ph.D., as Chief Executive Officer and as a director of the Company, effective October 1st, 2026.Dr. Warren brings more than two decades of experience in bioorganic chemistry, medicinal chemistry, peptide science and translational drug discovery. He is an Adjunct Associate Professor of Research in...
  6. FinanceDatavault AI Inc.Datavault AI CEO to Present "Operating System for Tokenized Assets" at XRP Seoul 2026PHILADELPHIA, PA, Oct 2, 2026 - Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that Nathaniel T. Bradley, CEO of Datavault AI, will present "Operating System for Tokenized Assets" at XRP Seoul 2026 on Oct. 3, 2026, at 3:05 p.m. KST at the Grand Hyatt Seoul in Seoul, South Korea. In the session, Bradley will explain why valuation, credentialing and verified metadata belong in a single operating layer beneath every real-world asset and how the Company's DataValue®, DataScore® and Information Data Exchange® technologies perform those functions in a single sequence beneath the point of issuance. "Tokenization gets treated as an issuance problem when it is really a data problem, and the Information Data Exchange exists to solve the data problem first," said Nathaniel T. Bradley, CEO of Datavault AI. "In Seoul, we will show the XRP Ledger community why valuation, credentialing and verified metadata have to live in one operating layer beneath the asset, and how our platform runs that sequence today." Bradley will also join the panel "How Traditional Finance Is Embracing Tokenization" at 5:40 p.m. KST. Datavault AI will exhibit at the conference and deploy its ADIO acoustic data transmission technology at its booth and from the keynote stage, where ADIO audio tones will direct attendees' mobile devices to registration and giveaway experiences. The Company's participation follows its appearances at XRP Tokyo 2026 and XRP Seoul 2025 and reflects its continued focus on expanding its presence and customer development across the Asia-Pacific region. Separately, Datavault AI will distribute the first XRP Seoul 2026 Limited Edition Collectible Token, a commemorative digital token minted on the XRP Ledger, to XRP Seoul 2026 attendees. The token is intended solely as a commemorative digital collectible for conference attendees and features a custom 3D design created for the event. Following Bradley's keynote, attendees can claim the token through the ADIO web app, which directs them to register or sign in to the Datavault AI platform, where the token is delivered to their account. "This is a historic first for XRP Seoul. We're thrilled to partner with Datavault AI to bring XRP Seoul's very first commemorative collectible to our attendees: a one-of-a-kind digital keepsake that marks a moment our global community will remember for years to come," said Ben Ko, Co-founder of XRPL Korea. About XRP Seoul 2026 XRP Seoul 2026 is a global conference focused on the XRP Ledger ecosystem, institutional blockchain adoption and real-world on-chain use cases. Hosted by XRPL Korea with Ripple as title sponsor, the event takes place on Oct. 3, 2026, at the Grand Hyatt Seoul. About Datavault AI Datavault AI™ (NASDAQ:DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI's platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company's technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai. Forward-Looking Statements This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. ("Datavault AI," the "Company," "us," "our," or "we") and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely," or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding future events, the planned creation of a commemorative digital token minted on the XRP Ledger and its distribution to XRP Seoul 2026 attendees through the ADIO web app and the Datavault AI platform, the anticipated presentation by the Company's CEO at XRP Seoul 2026 and the positions to be advanced in it, the described capabilities of the Company's DataValue, DataScore, and Information Data Exchange technologies and their application to real-world asset tokenization, the Company's planned exhibit presence, the planned deployment of ADIO acoustic data transmission technology at its booth and from the keynote stage, and the expected commercial relationships and customer development opportunities arising from the Company's Asia-Pacific expansion, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the Company's ability to create and distribute a commemorative digital token minted on the XRP Ledger to conference attendees through the ADIO web app and the Datavault AI platform as planned; the risk that the commemorative token is characterized by regulators as a security, virtual asset, or other regulated instrument in South Korea, the United States, or other jurisdictions; the Company's ability to present at and exhibit at XRP Seoul 2026 as planned; the Company's ability to deliver the described valuation, credentialing, and data exchange capabilities as a single operating layer for tokenized real-world assets; the Company's ability to deploy ADIO acoustic data transmission technology at the event venue; the Company's ability to convert event participation into commercial relationships or revenue in the Asia-Pacific region; changes in market demand for Datavault AI's services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to digital assets and tokenized assets in South Korea and other jurisdictions; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC's website at www.sec.gov, and could cause actual results to vary from expectations. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments it may make. Industry and Market Data Within this press release, we reference information and statistics regarding the market for our products. We have obtained some of this information and statistics from various independent third-party sources, including independent industry publications, reports by market research firms, and other independent sources. Some data and other information contained in this press release are also based on management's estimates and calculations, which are derived from our review and interpretation of internal surveys and independent sources. Data regarding the industries in which we compete and our market position and market share within these industries are inherently imprecise and are subject to significant business, economic and competitive uncertainties beyond our control, but we believe they generally indicate size, position and market share within this industry. While we believe such information is reliable, we have not independently verified any third-party information. While we believe our internal company research and estimates are reliable, such research and estimates have not been verified by any independent source. In addition, assumptions and estimates of our and our industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially from our assumptions and estimates. As a result, you should be aware that market, ranking and other similar industry data included in this press release, and estimates and beliefs based on that data, may not be reliable. Trademarks, Trade Names, Service Marks and Copyrights We own or have rights to use various trademarks, tradenames, service marks and copyrights, which are protected under applicable intellectual property laws. This press release also contains trademarks, tradenames, service marks and copyrights of other companies, which are, to our knowledge, the property of their respective owners. Solely for convenience, certain trademarks, tradenames, service marks and copyrights referred to in this press release may appear without the ©, ®, and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, tradenames, service marks and copyrights. We do not intend our use or display of other parties' trademarks, tradenames, service marks or copyrights to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties. Media Contact [email protected] Investor Contact Edward Barger VP, Investor Relations [email protected] © 2026 Datavault AI Inc. All Rights Reserved. SOURCE: Datavault AI Inc.
  7. HealthcareTargeted Cancer Therapy Market Size and Forecast by Therapy Type, Disease Indication, End-User, and Region, 2026-2035 | Precision Oncology Drives 6.8% CAGR Toward $175.48 BillionPrecision oncology, ADC innovation and radiopharmaceutical acquisitions drive growth, while strong U.S. approvals and hospital demand reinforce expansion
  8. IndustrialEurope Alpha-Emitting Radioligand Therapy Market Trends and Forecast to 2035 | 26% CAGR Drives Market Toward USD 0.40 Billion as Isotope Capacity and Oncology Pipelines ExpandBoost ROI by securing isotope supply, scaling GMP manufacturing, forming CDMO partnerships and targeting PSMA-led prostate cancer opportunities.
  9. HealthcareAscletis Pharma Inc.Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held...
  10. FinanceVietnam Veterinary Vaccine Import Market and Top 10 Importers Guide 2023-2026 | Import Reliance and Aquaculture Growth Create Market Entry OpportunitiesTarget Vietnam’s top veterinary vaccine importers with verified contacts and Excel data to accelerate customer acquisition, optimize supply chains and mitigate risk
  11. HealthcarePhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's First Prescription Drug for Cancer-Related FatigueRecognition highlights PhytoHealth's work in advancing PG2®, Taiwan's first approved botanical new drug, and raising clinical awareness of cancer-related fatigue — PhytoHealth Corporation CEO Angel Lee has been named one of Taiwan's 27th Ten Outstanding...
  12. HealthcareEverest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China's NMPA, Driving Continued Commercial MomentumHong Kong, Oct 2, 2026 - Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the application for localized manufacturing for VELSIPITY(R) (etrasimod arginine tablets) and granted Priority Review. Localized manufacturing of VELSIPITY(R) is expected to begin in 2027, further enhancing supply capacity and supply security in China and across the Asia-Pacific region. The acceptance marks progress in the Company’s planned commercialization of VELSIPITY(R). The VELSIPITY(R) localized production project has been progressing steadily since its launch at the Company’s global manufacturing facility in Jiashan in March 2025, with ongoing efforts focused on technology transfer, process optimization and preparations for localized manufacturing. Upon commencement of production, the facility is expected to have an annual production capacity of up to 50 million tablets, helping to strengthen supply stability, reduce manufacturing costs and improve operational efficiency, while supporting the commercialization of VELSIPITY(R). VELSIPITY(R) was approved by NMPA in February, 2026, for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. As a next-generation highly selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. The first prescription of VELSIPITY(R) in China was issued in March 2026, making its entry into clinical use. Alongside its rapid commercialization, the Company is actively participating in negotiations for the inclusion of VELSIPITY(R) in the National Reimbursement Drug List (NRDL). VELSIPITY(R) has been approved in several territories licensed to Everest Medicines, including mainland China, Hong Kong SAR, Macao SAR, Singapore, and South Korea, and is expected to receive NDA approval in Taiwan, China in the second half of 2026. On the clinical front, Ulcerative colitis (UC) is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC continue to increase, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 20311,2. Multiple studies of VELSIPITY(R) presented at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO 2026) and the 14th Annual Meeting of the Asian Organization for Crohn’s and Colitis (AOCC 2026) further supported its clinical profile. The data demonstrated sustained efficacy with continuous treatment for up to 3 years3. Durable benefit was observed in patients who had received only 5-ASA/thiopurine treatment, and in biologic-experienced patients4,5. Benefit was also demonstrated in patients with mildly to moderately active UC6, with favorable long-term safety and tolerability maintained for up to 5 years of treatment7. These findings further strengthen the clinical evidence base of VELSIPITY(R). The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY(R) was also included in the 2025 American College of Gastroenterology (ACG) Clinical Guideline, the 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and the 2026 European Crohn's and Colitis Organization (ECCO) Guidelines. Everest Medicines has a commercial-scale global manufacturing site in Jiashan, Zhejiang Province. It has established a complete GMP production quality management system complying with Chinese, EU and WHO standards and holds the manufacturing license. Localized manufacturing is expected to further enhance the commercial potential of VELSIPITY(R) by improving supply reliability and operational efficiency in China. Supported by Everest Medicines’ A2MS commercial operating system and lean management capabilities, the localized production of VELSIPITY(R) will strengthen the foundation for its continued expansion in China and further build the Company’s commercial capabilities in autoimmune diseases, supporting its long-term growth. Reference1. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679.2. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727.3. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.774.4. B E Sands, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1105.5. C Zheng, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1046.6. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.100.7. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1256.